Pharmaceutisch Weekblad

, Volume 8, Issue 6, pp 293–297 | Cite as

Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis

  • Y. A. Hekster
  • T. B. Vree
  • C. M. R. Weemaes
  • J. J. Rotteveel
Short Communications


The use of vancomycin is rapidly increasing due to the emergence of strains of staphylococci resistant to betalactam antibiotics. In this communication the pharmacokinetics of an overdose of vancomycin in a patient during continuous ambulatory peritoneal dialysis (CAPD) is reported. Brainstem auditory evoked potentials (BAEPs) are used to assess ototoxicity. It could be shown that by shortening the dwell time, the apparent CAPD flow was increased and the vancomycin clearance was also increased. This may explain in part the differences in the values of vancomycint1/2 in this patient (21 h) as compared to other studies (60–120 h). The age of the patient (3.5 years) may also have influenced thet1/2. Using brainstem auditory evoked potentials as a parameter to assess ototoxicity, it was shown that this patient suffered no damage from the overdose.

Key words

Ototoxicity Peritoneal dialysis, continuous ambulatory Pharmacokinetics Poisoning Vancomycin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kírby WMM. Vancomycin therapy of severe staphylococcal infections. J Antimicrob Chemother 1984; 14(suppl D): 73–8.PubMedGoogle Scholar
  2. 2.
    Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138–41.PubMedGoogle Scholar
  3. 3.
    Lau T, Barriere SL. Vancomycin nephrotoxicity. Drug Intell Clin Pharm 1985; 19: 907–8.Google Scholar
  4. 4.
    Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J. Antimicrob Chemother 1985; 16: 235–41.PubMedGoogle Scholar
  5. 5.
    Bunke CM, Aronoff GR, Brier ME, Sloan RC, Luft FC. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983; 34: 631–7.PubMedGoogle Scholar
  6. 6.
    Magera BE, Arroyo JC, Rosansky SJ, Postic B. Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis. Antimicrob Agents Chemother 1983; 23: 710–4.PubMedGoogle Scholar
  7. 7.
    Blevins RD, Halstenson CE, Salem NG, Matzke GR. Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1984; 25: 603–6.PubMedGoogle Scholar
  8. 8.
    Moellering RC. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984; 14(suppl D): 43–52.Google Scholar
  9. 9.
    Rogge MC, Johnson CA, Zimmerman SW, Welling PG, Vancomycin disposition during continuous ambulatory peritoneal dialysis: A pharmacokinetic analysis of peritoneal drug transport. Antimicrob Agents Chemother 1985; 27: 578–82.PubMedGoogle Scholar
  10. 10.
    Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986; 11: 257–82.PubMedGoogle Scholar
  11. 11.
    McIntosh ME, Smith WGJ, Forrest G, Brodie MJ. Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 1985; 28: 187–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Schaad KB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119–26.PubMedGoogle Scholar
  13. 13.
    Cunha BA, Quintiliani R, Deglin JM, Izard MW, Nightingale CH. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis 1981; suppl 3: S269–72.Google Scholar
  14. 14.
    Pechere JC, Bernard PA, Ferron P, Rouillard R, Picard AC, Murray G. Assessment of minute aminoglycoside ototoxicity by evoked audiometry in humans. In: Periti P, Grassi GG eds. Current Chemotherapy and Immunotherapy. Proceedings of the 12th International Congress of Chemotherapy, Florence, Italy, 19–24, July, 1981. Washington: American Society for Microbiology, 1981: 843–4.Google Scholar
  15. 15.
    Robert CS. Multisensory evoked potentials in experimental and applied neurotoxicology. Neurobehav Toxicol Teratol 1983; 5: 659–71.PubMedGoogle Scholar
  16. 16.
    Arezzo JC, Simson R, Bronnan NE. Evoked potentials in the assessment of neurotoxicity in humans. Neurobehav Toxicol Teratol 1985; 7: 299–304.PubMedGoogle Scholar
  17. 17.
    Kavanagh KT, McCabe BF. Ototoxicity of oral neomycin and vancomycin. Laryngoscope 1983; 93: 649–53.PubMedGoogle Scholar
  18. 18.
    Rotteveel JJ, Colon EJ, Notermans SLH, Stoelinga GBA, Visco YM, De Graaf R. The central auditory conduction at term date and three months of age. II. Auditory brainstem response. Scand Audiol 1986; 15: 11–9.PubMedGoogle Scholar
  19. 19.
    Golper T, Bennett W, Jones S. Peritonitis associated with chronic peritoneal dialysis. Dial Transplant 1978; 7: 1173–8.Google Scholar
  20. 20.
    Janknegt R, Koks CHW. Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review. Pharm Weekbl [Sci] 1984; 6: 229–36.Google Scholar
  21. 21.
    Levey A, Harrington J. Continuous peritoneal dialysis for chronic renal failure. Medicine 1982; 61: 330–9PubMedGoogle Scholar
  22. 22.
    Matzke GR. Vancomycin. In: Evans E, Schentag JE, Jusko WJ, et al., eds., Applied Pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Spokane: Applied Therapeutics Inc., 1986; 399–436.Google Scholar
  23. 23.
    Eggermont JJ. The inadequacy of click-evoked auditory brainstem responses in audiological applications. Ann NY Acad Sci 1982; 380: 707–9.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1986

Authors and Affiliations

  • Y. A. Hekster
    • 1
  • T. B. Vree
    • 1
  • C. M. R. Weemaes
    • 2
  • J. J. Rotteveel
    • 2
  1. 1.Department of Clinical Pharmacy, St. Radboud HospitalCatholic University of NijmegenNijmegenThe Netherlands
  2. 2.Department of Paediatrics, St. Radboud HospitalCatholic University of NijmegenNijmegenThe Netherlands

Personalised recommendations